Henry J. Riordan, PhD
Chief Development Officer
Dr. Riordan is Chief Development Officer and a co-founder of Worldwide Clinical Trials. He has been involved in the assessment, treatment and investigation of various neuroscience drugs and disorders in both industry and academia for the past 30 years. Dr. Riordan has advanced training and expertise in quantitative methods, biostatistics, experimental design, neurophysiology, neuroimaging, and clinical neuropsychology . He has over 125 publications, including co-authoring two books focusing on innovative CNS clinical trials methodology. As CDO, he is responsible for bringing together Worldwide assets across business units and connecting the critical functions that serve to differentiate Worldwide. These assets all aim to improve data quality and include scientific solutions, rater training, clinical trial liaison and endpoint adjudication teams. Dr. Riordan and teams offer early engagement consultancy services, regulatory strategies, dossier consulting, and review/preparation for regulatory agency interactions. In addition, he supports operational teams to ensure successful study conduct through specialized assessments and measures such as CSF, neuroimaging and cognition biomarkers. He routinely provides support to KOL, EA and DSMB meetings including member identification and participation.
Ask Dr. Riordan a question
Submit an RFP. Ask a Question
Dr. Riordan brings together Worldwide’s scientific assets across the CNS, general medicine, cardiometabolic, and oncology divisions and connecting the critical functions that serve to differentiate Worldwide by implementing strategies and tactics consistent with the company’s vision of being the leader in the application of rigorous methodology and medically/scientifically advanced drug development processes producing reliable data to support highly informed health care decisions. He has been involved in the assessment, treatment and investigation of various CNS disorders in both industry and academia for more than 20 years, was one of the original Worldwide team members beginning in 1998 and is a cofounder of the current Worldwide.
Dr. Riordan has been the primary author of numerous protocols in neurologic, psychiatric, and analgesic indications across all phases of development. He has been involved in several clinical development programs and has participated in numerous advisory boards and regulatory interactions. During his tenure as the Clinical Lead for Worldwide’s Early Phase Development Unit, he was responsible for helping to establish the Specialized Patient Study Unit. He also spent several years in the departments of neurology and psychiatry at Jefferson, the University of Pennsylvania, and Dartmouth medical schools.
Dr. Riordan holds a BA in psychology and biology from Bloomsburg University of Pennsylvania, an MA in experimental psychology: quantitative methods from University of Hartford, an MA in biopsychology from Stony Brook University, and a PhD in biopsychology, specialty in neuropsychology, from State University of New York at Stony Brook.
